Abstract：
Platinum (II) drugs, including cisplatin, carboplatin, and oxaliplatin, have achieved significant clinical success in cancer treatment. However, their clinical application has been greatly hindered by various adverse factors such as non-specific activation and drug resistance. Compared with Pt(II) drugs, the axial ligands within Pt(IV) compounds can improve the pharmacokinetic properties, selectivity, and biological activity, implementing alternative cytotoxic mechanisms beyond DNA cross-linking and partially overcoming drug resistance. The controlled conversion of Pt(IV) prodrugs into Pt(II) agents at the tumor site has been extensively explored internationally. In this review, Pt(IV) prodrug modification strategies are first summarized, next the development of the predominant external and internal photosensitizers is listed. Finally, three representative photoreduction mechanisms and strategies for developing corresponding Pt(IV) prodrugs are discussed. This work provides constructive instruction for the subsequent molecular design of Pt(IV) prodrugs. .
摘要：
铂金（II）药物，包括顺铂,卡铂,还有奥沙利铂,在癌症治疗方面取得了显著的临床成功。然而,非特异性激活和耐药性等多种不良因素极大地阻碍了其临床应用。与铂(Ⅱ)类药物相比，Pt（IV）化合物中的轴向配体可以改善药代动力学性质，选择性,和生物活性，实施DNA交联和部分克服耐药性之外的替代细胞毒性机制。在肿瘤部位将Pt(IV)前药控制转化为Pt(II)剂已在国际上得到广泛探索。在这次审查中,首先总结了Pt(IV)前药修饰策略,接下来列出了主要的外部和内部光敏剂的开发。最后,讨论了三种代表性的光还原机制和开发相应的Pt（IV）前药的策略。这项工作为随后的Pt（IV）前药的分子设计提供了建设性的指导。。
